½ÃÀ庸°í¼­
»óǰÄÚµå
1288782

¼¼°èÀÇ Áý´Ü°ËÁø ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2023-2030³â)

Global Population Screening Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 339 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Áý´Ü°ËÁø ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023-2030³âÀÇ Á¶»ç ±â°£ Áß ¿¬Æò±Õ 7.48%ÀÇ CAGR·Î 2022³â 353¾ï ´Þ·¯¿¡¼­ 2030³â ¾à 675¾ï 7,000¸¸ ´Þ·¯ ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

Áý´Ü°ËÁøÀº ƯÁ¤ Áúº´À̳ª °Ç°­ »óÅÂÀÇ Á¸À縦 È®ÀÎÇϱâ À§ÇØ ¸¹Àº ¼öÀÇ °³ÀÎ(ÀϹÝÀûÀ¸·Î ƯÁ¤ Áý´Ü)À» ü°èÀûÀ¸·Î °Ë»çÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. Áý´Ü°ËÁøÀÇ ¸ñÀûÀº Ä¡·á°¡ ´õ È¿°úÀûÀÌ°í ´õ ³ªÀº °Ç°­ °á°ú¸¦ °¡Á®¿Ã ¼öÀÖ´Â Ãʱ⠴ܰ迡¼­ Áúº´À̳ª »óŸ¦ ¹ß°ßÇÏ´Â °ÍÀÔ´Ï´Ù. Áý´Ü°ËÁø¿¡´Â Ç÷¾× °Ë»ç, ¿µ»ó °Ë»ç, ½Åü °Ë»ç µî ´Ù¾çÇÑ °Ë»ç°¡ Æ÷ÇԵ˴ϴÙ. Áý´Ü°ËÁø ÇÁ·Î±×·¥ÀÇ ¿¹·Î´Â À¯¹æÃÔ¿µ¼ú °ËÁø(À¯¹æ¾Ï), ÀڱðæºÎ¾Ï °ËÁø(ÀڱðæºÎ¾Ï), ´ëÀå³»½Ã°æ °ËÁø(´ëÀå¾Ï) µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áý´Ü°ËÁøÀº ½ÉÀ庴¿¡ ´ëÇÑ ÄÝ·¹½ºÅ×·Ñ ¹× Ç÷¾Ð °Ë»ç¿Í °°Àº ƯÁ¤ ÁúȯÀÇ À§Çè ¿äÀÎÀ» ÆÄ¾ÇÇÏ´Â µ¥¿¡µµ »ç¿ëµË´Ï´Ù. Áý´Ü°ËÁø ÇÁ·Î±×·¥Àº ÀϹÝÀûÀ¸·Î ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ³ª °øÁß º¸°Ç ±â°ü¿¡ ÀÇÇØ Á¶Á÷µÇ°í ½ÃÇàµÇ¸ç, Á¾Á¾ Á¤ºÎ ÀÚ±ÝÀ¸·Î Áö¿øµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. Áý´Ü°ËÁø ÇÁ·Î±×·¥ÀÇ ¼³°è¿Í ½ÇÇàÀº ´ë»ó Áúº´À̳ª »óÅÂ, °ËÁø ´ë»ó Áý´ÜÀÇ Æ¯¼º, »ç¿ë °¡´ÉÇÑ °ËÁø ¹æ¹ý ¹× ±â¼ú¿¡ µû¶ó ´Þ¶óÁú ¼ö ÀÖ½À´Ï´Ù. Áý´Ü°ËÁøÀº Áúº´À̳ª »óŸ¦ Á¶±â¿¡ ¹ß°ßÇÏ´Â È¿°úÀûÀÎ ¹æ¹ýÀÌÁö¸¸, ´ÜÁ¡µµ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ÀϺΠ¼±º° °Ë»ç´Â À§¾ç¼º ¶Ç´Â À§À½¼º °á°ú¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ºÒÇÊ¿äÇÑ °ÆÁ¤°ú Áø´ÜÀ» °£°úÇÏ´Â °á°ú¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀϺΠ°³ÀÎÀº Á¢±Ù¼ºÀÌ ¶³¾îÁö°Å³ª ÇÁ¶óÀ̹ö½Ã ¹× ÈÄ¼Ó Á¶Ä¡ ºñ¿ë¿¡ ´ëÇÑ ¿ì·Á µî ¿©·¯ °¡Áö ÀÌÀ¯·Î ¼±º° °Ë»ç ÇÁ·Î±×·¥¿¡ Âü¿©ÇÏÁö ¾Ê±â·Î °áÁ¤ÇÑ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ :

Áý´Ü°ËÁø ÇÁ·Î±×·¥Àº Ä¡·á È¿°ú°¡ ³ôÀº ¸¸¼ºÁúȯÀ» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ ÁúȯÀÇ ºÎ´ãÀ» ÁÙÀÌ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ±â¼ú ¹× °ËÁø ¹æ¹ýÀÇ ¹ßÀüÀ¸·Î Áý´Ü°ËÁø ÇÁ·Î±×·¥Àº ´õ¿í Á¤È®Çϰí È¿À²ÀûÀÌ¸ç ºñ¿ë È¿À²ÀûÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î »õ·Î¿î ¿µ»ó ±â¼ú°ú ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç¸¦ ÅëÇØ Áúº´À» ´õ ºü¸£°í Á¤È®ÇÏ°Ô ¹ß°ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¼¼°è ¸¹Àº Á¤ºÎµéÀº Àα¸ °ËÁø ÇÁ·Î±×·¥ÀÇ Á߿伺À» ÀνÄÇϰí ÀÌ·¯ÇÑ ÇÁ·Î±×·¥À» È®´ëÇϱâ À§ÇØ Àڱݰú Áö¿øÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ´Â Àα¸ °ËÁø ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. Àα¸ °ËÁøÀÇ ÀÌÁ¡ÀÌ »ç¶÷µé¿¡°Ô ÀÎ½ÄµÇ°í °ËÁø ÇÁ·Î±×·¥ÀÇ Á¤È®¼º°ú È¿°ú°¡ Çâ»óµÊ¿¡ µû¶ó ÀÌ·¯ÇÑ ÇÁ·Î±×·¥ÀÇ ¼ö¿ë°ú ¼ö¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. »ç¶÷µéÀº °Ç°­À» À¯ÁöÇϰí Áúº´ ¹ßº´À» ¿¹¹æÇϱâ À§ÇØ ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Áý´Ü°ËÁø ÇÁ·Î±×·¥Àº ¿¹¹æ ÀÇ·áÀÇ Áß¿äÇÑ ºÎºÐÀ̱⠶§¹®¿¡ ÀÌ·¯ÇÑ ÇÁ·Î±×·¥¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀÌ Á¶»ç º¸°í¼­´Â Portre's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº ¾÷°è ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·Âµµ¸¦ Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ÅøÀº ¼¼°è Áý´Ü°ËÁø ½ÃÀåÀÇ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. Áý´Ü°ËÁø »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº º» ¿¬±¸¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.

Áö¿ªº° ºÐ¼® :

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Áý´Ü°ËÁø ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ÀÌ Á¶»ç º¸°í¼­´Â ½ÃÀå ÁÖ¿ä ±â¾÷ÀÇ Á¾ÇÕÀû °³¿ä¿Í ¼¼°è °æÀï ȯ°æ¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ °üÁ¡À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ ¼½¼ÇÀº ÁÖ¿ä M&A, ¹Ì·¡ ¿ª·®, ÆÄÆ®³Ê½Ê, À繫 °³¿ä, Çù¾÷, ½ÅÁ¦Ç° °³¹ß, ½ÅÁ¦Ç° Ãâ½Ã µî ´Ù¾çÇÑ Àü·«Àû ¹ßÀüÀ» Æ÷ÇÔÇÑ °æÀï ±¸µµÀÇ ÀüüÀûÀÎ °üÁ¡À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù..

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀåÀÇ ½º³À¼ô

Á¦3Àå Áý´Ü°ËÁø - »ê¾÷ ºÐ¼®

  • ¼­·Ð - ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • »ê¾÷ µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • ´ÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ÀδÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³ÎÀÇ µ¿Çâ

Á¦5Àå COVID-19 ¹ß»ýÀÇ ¿µÇ⠺м®

Á¦6Àå ¼¼°èÀÇ Áý´Ü°ËÁø ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • Áö¿ªº° ºÐ¼®
  • ±¹°¡
  • ÁÖ

Á¦7Àå ¼¼°èÀÇ Áý´Ü°ËÁø ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • Á¦Ç°º° °³¿ä
  • ½ÇÀû°ú ¿¹Ãø µ¥ÀÌÅÍ
  • Á¦Ç°º° ºÐ¼®
  • Çϵå¿þ¾î ±â±â(±â±â, ŰƮ, Ĩ)
  • °Ë»ç/·¦(¼­ºñ½º)
  • ºÐ¼®/ÇØ¼®(ÆÛ½º³Î¶óÀÌÁ¦À̼ǰú ÇØ¼®)

Á¦8Àå ¼¼°èÀÇ Áý´Ü°ËÁø ½ÃÀå ºÐ¼® : »ç¾÷º°

  • »ç¾÷º° °³¿ä
  • ½ÇÀû°ú ¿¹Ãø µ¥ÀÌÅÍ
  • »ç¾÷º° ºÐ¼®
  • º´¿ø
  • ¿¬±¸±â°ü
  • Áø´Ü ·¦

Á¦9Àå ¼¼°èÀÇ Áý´Ü°ËÁø ½ÃÀå ºÐ¼® : ¼ºº°

  • ¼ºº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ¼ºº° ºÐ¼®
  • ³²¼º
  • ¿©¼º

Á¦10Àå ¼¼°èÀÇ Áý´Ü°ËÁø ½ÃÀå ºÐ¼® : À¯Çüº°

  • À¯Çüº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • À¯Çüº° ºÐ¼®
  • ¸Å½º
  • ÇÁ¸®¹Ì¾ö

Á¦11Àå ¼¼°èÀÇ Áý´Ü°ËÁø ½ÃÀå ºÐ¼® : ¿¬·Éº°

  • ¿¬·Éº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ¿¬·Éº° ºÐ¼®
  • 15¼¼ ¹Ì¸¸
  • 15-65¼¼
  • 65¼¼ ÀÌ»ó

Á¦12Àå ¼¼°èÀÇ Áý´Ü°ËÁø ½ÃÀå ÆÇ¸Å ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹ÌÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • UAE
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ

Á¦13Àå Áý´Ü°ËÁø ±â¾÷ÀÇ °æÀï ±¸µµ

  • Áý´Ü°ËÁø ½ÃÀå °æÀï
  • Á¦ÈÞ¡¤Çù¾÷¡¤ÇÕÀÇ
  • ÇÕº´¡¤Àμö
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦14Àå ±â¾÷ °³¿ä

  • TOP ±â¾÷ÀÇ Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Agilent Technologies Inc.
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° ¼Ò°³
    • ÃÖ±Ù °³¹ß »óȲ
  • Thermo Fisher Scientific Inc.
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • QIAGEN
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • F. Hoffmann-La Roche Ltd.
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • Quest Diagnostics
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • Illumina Inc.
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • ARUP Laboratories
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • Novogene Co. Ltd.
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • LGC Limited
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • Gene Gene Ltd.
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù µ¿Çâ

ÁÖ : ±â¾÷ °³¿ä¿¡¼­ À繫ÀÇ »ó¼¼ ³»¿ª°ú Ãֽа³¹ßÀº ÀÔ¼ö »óȲ¿¡ µû¶ó Á¦°ø °¡´ÉÇϳª ºñ°ø°³ ȸ»çÀÇ °æ¿ì, ´Ù·çÁö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù.

KSA 23.07.05

The global demand for Population Screening Market is presumed to reach the market size of nearly USD 67.57 BN by 2030 from USD 35.3 BN in 2022 with a CAGR of 7.48% under the study period 2023-2030.

Population screening refers to the systematic testing of a large group of individuals, typically a specific population, to identify the presence of a particular disease or health condition. The goal of population screening is to detect the disease or condition at an early stage when treatment is more effective and can lead to better health outcomes. Population screening can involve a variety of tests, including blood tests, imaging tests, and physical exams. Examples of population screening programs include mammography screening (breast cancer, Pap smear screening (cervical cancer), and colonoscopy screening(colon cancer). Population screening can also be used to identify risk factors for certain diseases, such as cholesterol and blood pressure screening for heart disease. Population screening programs are typically organized and implemented by healthcare providers or public health agencies, often with support from government funding. The design and implementation of population screening programs can vary depending on the disease or condition being targeted, the characteristics of the population being screened, and the available screening methods and technology. While population screening can be an effective way to identify diseases and conditions at an early stage, it can also have drawbacks. For example, some screening tests can produce false-positive or false-negative results, leading to unnecessary worry or missed diagnoses. Additionally, some individuals may choose not to participate in screening programs for various reasons, including lack of access or concerns about privacy or the cost of follow-up care.

Market Dynamics:

Population screening programs can help to detect chronic diseases at an early stage, when treatment is more effective, and thus play an important role in reducing the burden of these diseases. Advances in technology and screening methods are making population screening programs more accurate, efficient, and cost-effective. For example, new imaging technologies and biomarker tests are enabling earlier and more accurate detection of diseases. Many governments around the world are recognizing the importance of population screening programs and are providing funding and support to expand these programs. This is driving the growth of the population screening market. As people become aware of the benefits of population screening and the accuracy and efficacy of screening programs improve, the acceptance and uptake of these programs are increasing. There is a growing trend towards preventive healthcare, as people seek to maintain their health and prevent the onset of diseases. Population screening programs are an important part of preventive healthcare, and the demand for these programs is therefore increasing.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of population screening. The growth and trends of population screening industry provide a holistic approach to this study.

Market Segmentation:

This section of the population screening market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Geography

  • Nation
  • State

By Product

  • Hardware Equipment (Instrument, Kits, Chips)
  • Testing / Lab (Services)
  • Analytics / Interpretation (Personalization And Interpretation)

By Business

  • Hospitals
  • Research Institutes
  • Diagnostic Labs

By Gender

  • Male
  • Female

By Type

  • Mass
  • Premium

By Age

  • Ages <15
  • 15-65
  • Ages 65+

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Population Screening market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the population screening market include Agilent Technologies Inc., Thermo Fisher Scientific, Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Quest Diagnostics, Illumina Inc., ARUP Laboratories, Novogene Co. Ltd., LGC Limited, Gene by Gene Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . POPULATION SCREENING - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Geography
    • 3.7.2 Market Attractiveness Analysis By Product
    • 3.7.3 Market Attractiveness Analysis By Business
    • 3.7.4 Market Attractiveness Analysis By Gender
    • 3.7.5 Market Attractiveness Analysis By Type
    • 3.7.6 Market Attractiveness Analysis By Age
    • 3.7.7 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL POPULATION SCREENING MARKET ANALYSIS BY GEOGRAPHY

  • 6.1 Overview by Geography
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Geography
  • 6.4 Nation Historic and Forecast Sales by Regions
  • 6.5 State Historic and Forecast Sales by Regions

7 . GLOBAL POPULATION SCREENING MARKET ANALYSIS BY PRODUCT

  • 7.1 Overview by Product
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Product
  • 7.4 Hardware Equipment (Instrument, Kits, Chips) Historic and Forecast Sales by Regions
  • 7.5 Testing / Lab (Services) Historic and Forecast Sales by Regions
  • 7.6 Analytics / Interpretation (Personalization And Interpretation) Historic and Forecast Sales by Regions

8 . GLOBAL POPULATION SCREENING MARKET ANALYSIS BY BUSINESS

  • 8.1 Overview by Business
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Business
  • 8.4 Hospitals Historic and Forecast Sales by Regions
  • 8.5 Research Institutes Historic and Forecast Sales by Regions
  • 8.6 Diagnostic Labs Historic and Forecast Sales by Regions

9 . GLOBAL POPULATION SCREENING MARKET ANALYSIS BY GENDER

  • 9.1 Overview by Gender
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by Gender
  • 9.4 Male Historic and Forecast Sales by Regions
  • 9.5 Female Historic and Forecast Sales by Regions

10 . GLOBAL POPULATION SCREENING MARKET ANALYSIS BY TYPE

  • 10.1 Overview by Type
  • 10.2 Historical and Forecast Data
  • 10.3 Analysis by Type
  • 10.4 Mass Historic and Forecast Sales by Regions
  • 10.5 Premium Historic and Forecast Sales by Regions

11 . GLOBAL POPULATION SCREENING MARKET ANALYSIS BY AGE

  • 11.1 Overview by Age
  • 11.2 Historical and Forecast Data
  • 11.3 Analysis by Age
  • 11.4 Ages <15 Historic and Forecast Sales by Regions
  • 11.5 15-65 Historic and Forecast Sales by Regions
  • 11.6 Ages 65+ Historic and Forecast Sales by Regions

12 . GLOBAL POPULATION SCREENING MARKET SALES ANALYSIS BY GEOGRAPHY

  • 12.1. Regional Outlook
  • 12.2. Introduction
  • 12.3. North America Sales Analysis
    • 12.3.1. Overview, Historic and Forecast Sales Analysis
    • 12.3.2. North America By Segment Sales Analysis
    • 12.3.3. North America By Country Sales Analysis
    • 12.3.4. United State Sales Analysis
    • 12.3.5. Canada Sales Analysis
    • 12.3.6. Mexico Sales Analysis
  • 12.4. Europe Sales Analysis
    • 12.4.1. Overview, Historic and Forecast Sales Analysis
    • 12.4.2. Europe by Segment Sales Analysis
    • 12.4.3. Europe by Country Sales Analysis
    • 12.4.4. United Kingdom Sales Analysis
    • 12.4.5. France Sales Analysis
    • 12.4.6. Germany Sales Analysis
    • 12.4.7. Italy Sales Analysis
    • 12.4.8. Russia Sales Analysis
    • 12.4.9. Rest Of Europe Sales Analysis
  • 12.5. Asia Pacific Sales Analysis
    • 12.5.1. Overview, Historic and Forecast Sales Analysis
    • 12.5.2. Asia Pacific by Segment Sales Analysis
    • 12.5.3. Asia Pacific by Country Sales Analysis
    • 12.5.4. China Sales Analysis
    • 12.5.5. India Sales Analysis
    • 12.5.6. Japan Sales Analysis
    • 12.5.7. South Korea Sales Analysis
    • 12.5.8. Australia Sales Analysis
    • 12.5.9. Rest Of Asia Pacific Sales Analysis
  • 12.6. Latin America Sales Analysis
    • 12.6.1. Overview, Historic and Forecast Sales Analysis
    • 12.6.2. Latin America by Segment Sales Analysis
    • 12.6.3. Latin America by Country Sales Analysis
    • 12.6.4. Brazil Sales Analysis
    • 12.6.5. Argentina Sales Analysis
    • 12.6.6. Peru Sales Analysis
    • 12.6.7. Chile Sales Analysis
    • 12.6.8. Rest of Latin America Sales Analysis
  • 12.7. Middle East & Africa Sales Analysis
    • 12.7.1. Overview, Historic and Forecast Sales Analysis
    • 12.7.2. Middle East & Africa by Segment Sales Analysis
    • 12.7.3. Middle East & Africa by Country Sales Analysis
    • 12.7.4. Saudi Arabia Sales Analysis
    • 12.7.5. UAE Sales Analysis
    • 12.7.6. Israel Sales Analysis
    • 12.7.7. South Africa Sales Analysis
    • 12.7.8. Rest Of Middle East And Africa Sales Analysis

13 . COMPETITIVE LANDSCAPE OF THE POPULATION SCREENING COMPANIES

  • 13.1. Population Screening Market Competition
  • 13.2. Partnership/Collaboration/Agreement
  • 13.3. Merger And Acquisitions
  • 13.4. New Product Launch
  • 13.5. Other Developments

14 . COMPANY PROFILES OF POPULATION SCREENING INDUSTRY

  • 14.1. Top Company Share Analysis
  • 14.2. Market Concentration Rate
  • 14.3. Agilent Technologies Inc.
    • 14.3.1. Company Overview
    • 14.3.2. Company Revenue
    • 14.3.3. Products
    • 14.3.4. Recent Developments
  • 14.4. Thermo Fisher Scientific Inc.
    • 14.4.1. Company Overview
    • 14.4.2. Company Revenue
    • 14.4.3. Products
    • 14.4.4. Recent Developments
  • 14.5. QIAGEN
    • 14.5.1. Company Overview
    • 14.5.2. Company Revenue
    • 14.5.3. Products
    • 14.5.4. Recent Developments
  • 14.6. F. Hoffmann-La Roche Ltd.
    • 14.6.1. Company Overview
    • 14.6.2. Company Revenue
    • 14.6.3. Products
    • 14.6.4. Recent Developments
  • 14.7. Quest Diagnostics
    • 14.7.1. Company Overview
    • 14.7.2. Company Revenue
    • 14.7.3. Products
    • 14.7.4. Recent Developments
  • 14.8. Illumina Inc.
    • 14.8.1. Company Overview
    • 14.8.2. Company Revenue
    • 14.8.3. Products
    • 14.8.4. Recent Developments
  • 14.9. ARUP Laboratories
    • 14.9.1. Company Overview
    • 14.9.2. Company Revenue
    • 14.9.3. Products
    • 14.9.4. Recent Developments
  • 14.10. Novogene Co. Ltd.
    • 14.10.1. Company Overview
    • 14.10.2. Company Revenue
    • 14.10.3. Products
    • 14.10.4. Recent Developments
  • 14.11. LGC Limited
    • 14.11.1. Company Overview
    • 14.11.2. Company Revenue
    • 14.11.3. Products
    • 14.11.4. Recent Developments
  • 14.12. Gene Gene Ltd.
    • 14.12.1. Company Overview
    • 14.12.2. Company Revenue
    • 14.12.3. Products
    • 14.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦